Drug Trial Radar · NCT04727034
Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy
Last checked: Nov 20, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,800
Planned (sponsor's estimate)
Start
Mar 2, 2021
Primary completion
Jul 1, 2023
Study completion Aug 1, 2023
Sponsor
- Lead sponsor
- RenJi HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai East Hospital; Affiliated Hospital of Jiaxing University; The Second Affiliated Hospital of Jiaxing University; The First Affiliated Hospital of Nanchang University
- First posted
- Jan 27, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high. Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.
Conditions
- Hypoxia
- Gastric Cancer
- Sedation Complication
- Propofol Adverse Reaction
Interventions
Remimazolam tosylateDrug
Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.
PropofolDrug
Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The success rate of remazolam tosylate for sedation in gastroscopy diagnosis and treatmentTime frame: Patients will be followed for the duration of hospital stay, an expected average of 2 hours
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Jiaxing University
Jiaxing, China · Recruiting
The Second Affifiliated Hospital of Jiaxing University
Jiaxing, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
Renji Hospital
Shanghai, Shanghai, China, China · Recruiting
Shanghai East Hospital
Shanghai, Shanghai, China, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.